Human Molecular Genetics Advance Access originally published online on March 6, 2007
Human Molecular Genetics 2007 16(9):1058-1071; doi:10.1093/hmg/ddm053
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Comparative genomic and functional analyses reveal a novel cis-acting PTEN regulatory element as a highly conserved functional E-box motif deleted in Cowden syndrome
1 Genomic Medicine Institute, 2 Lerner Research Institute and 3 Taussig Cancer Center, Cleveland Clinic Foundation, 9500 Euclid Avenue, NE-50, Cleveland, OH 44195, USA, 4 Department of Genetics and 5 CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA
* To whom correspondence should be addressed. Tel: +1 2164443440; Fax: +1 2166360655; Email: engc{at}ccf.org
Received February 4, 2007; Accepted February 28, 2007
Germline mutations in PTEN, encoding a phosphatase on 10q23, cause Cowden syndrome (CS) and Bannayan–Riley–Ruvalcaba syndrome (BRRS). Approximately, 10% of CS-related PTEN mutations occur in the PTEN promoter and 11% of BRRS-related mutations include large deletions, often favoring the gene's 5' end (exon 1, promoter). In order to better understand the mechanism(s) underlying the deregulation of PTEN in these syndromes, it is important that functional cis-regulatory elements be identified. We employed a comparative genomic approach combined with molecular genetic techniques to identify a highly conserved sequence upstream of the PTEN promoter, sharing 80% sequence identity among Homo sapiens, Mus musculus and Rattus norvegicus. Within this region, we identified a canonical E-box sequence (CACGTG) located at position –2181 to –2176, approximately 800 bp upstream of the PTEN core promoter and more than 1.1 kb upstream of its minimal promoter region (located at –958 to –821). In vitro assays suggest that this motif is recognized by members of the basic region-helix-loop-helix-leucine-zipper (bHLH-LZ) transcription factor family, USF1 and USF2, and reporter assays indicate that this novel E-box is involved in mediating PTEN transcriptional activation. Four of 30 CS/CS-like patients, without previously identified PTEN mutations, were found with germline deletions of the E-box element. Of the four, three had deletions stretching to exon 1, but not 3' of it; importantly, one classic CS patient harbored a germline deletion localizing to this E-box region, further affirming the role of this element in PTEN's regulation and deregulation, and its contribution to the pathogenesis of CS.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  X. Chen, J. Weaver, B. A. Bove, L. A. Vanderveer, S. C. Weil, A. Miron, M. B. Daly, and A. K. Godwin Allelic imbalance in BRCA1 and BRCA2 gene expression is associated with an increased breast cancer risk Hum. Mol. Genet., May 1, 2008; 17(9): 1336 - 1348. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Weber and C. Eng Update on the Molecular Diagnosis of Endocrine Tumors: Toward -omics-Based Personalized Healthcare? J. Clin. Endocrinol. Metab., April 1, 2008; 93(4): 1097 - 1104. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. E. Teresi, S. M. Planchon, K. A. Waite, and C. Eng Regulation of the PTEN promoter by statins and SREBP Hum. Mol. Genet., April 1, 2008; 17(7): 919 - 928. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Rottmann, S. Speckgens, J. Luscher-Firzlaff, and B. Luscher Inhibition of apoptosis by MAD1 is mediated by repression of the PTEN tumor suppressor gene FASEB J, April 1, 2008; 22(4): 1124 - 1134. [Abstract] [Full Text] [PDF]
|
|